Cetuximab

BNF:: Immune System & Malignant Disease
Status:: Do Not Prescribe (DNP), Red
Decision Date:: None

Comments

RED:

NICE TA439: cetuximab and panitumumab for previously untreated metastatic colorectal cancer. (Decision date - May 2017).
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck. (Decision date - Oct 2017).

Do Not Prescribe (DNP):

NICE TA242: Colorectal cancer (metastatic) 2nd line. Cetuximab – not recommended alone or in combination. (Decision date - Feb 2012).

NHS England commissioned - to be used in line with NHSE commissioning intentions.

This drug can be funded through the cancer drug fund - seek advice from oncologist/haematologist

Red Drug Classifications

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)